Worcestershire Royal Hospital
Welcome,         Profile    Billing    Logout  
 7 Trials 
11 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Greenwood, John P
EXCELLENT, NCT02669810: (EXpanded CELL ENdocardiac Transplantation)

Completed
2
49
Europe
PROTHERACYTES, Standard Treatment for CHF post AMI
CellProthera
Acute Myocardial Infarction
03/24
03/24
OPTIMAL, NCT04111770: The Randomized Controlled Trial

Active, not recruiting
N/A
807
Europe
IVUS guided Percutaneous Coronary Intervention, QCA guided Percutaneous Coronary Intervention
ECRI bv, Philips Healthcare, Boston Scientific Corporation
Left Main Coronary Artery Stenosis
07/25
07/25
Shafeek, Salim
FiTNEss, NCT03720041 / 2018-003590-10: Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
740
Europe
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, Ninlaro, Revlimid, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance, R2: Lenalidomide + ixazomib maintenance
University of Leeds, Cancer Research UK, Takeda, Celgene
Multiple Myeloma
12/24
12/24
Shafik, Saleem
ACCoRd, NCT03562169: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII

Recruiting
3
406
Europe
Ixazomib, thalidomide, & dexamethasone (ITD) re-induction, Conventional autologous stem cell transplant (ASCT-con), Augmented autologous stem cell transplant (ASCT-aug), ITD consolidation and ixazomib maintenance vs. No further therapy
University of Leeds, Cancer Research UK, Takeda
Multiple Myeloma
03/26
03/27
Trevelyan, Jasper
NCT04859985: The SELUTION DeNovo Study

Active, not recruiting
N/A
3326
Europe, RoW
SELUTION SLR, DES
M.A. Med Alliance S.A.
Coronary Artery Disease
08/25
07/30
Arya, Anita
PRAETORIAN-DFT, NCT03495297: A Randomised Trial of S-ICD Implantation with and Without Defibrillation Testing

Active, not recruiting
N/A
965
Europe, US
ommitence of defibrillation testing
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Boston Scientific Corporation
Ventricular Arrythmia
04/25
07/25
Routledge, Helen
NAGOMI COMPLEX, NCT05705973: Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

Recruiting
N/A
3000
Europe
Ultimaster Nagomi™
Terumo Europe N.V.
Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
09/26
09/27
Trevelyan
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
Contact, First
PARTNER, NCT03150576: Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Recruiting
2/3
780
Europe
Olaparib, Lynparza, Paclitaxel and Carboplatin, Taxol and Paraplatin
Cambridge University Hospitals NHS Foundation Trust, AstraZeneca, Cancer Research UK
Breast Cancer
06/24
06/34
Churn, Mark
PARTNER, NCT03150576: Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Recruiting
2/3
780
Europe
Olaparib, Lynparza, Paclitaxel and Carboplatin, Taxol and Paraplatin
Cambridge University Hospitals NHS Foundation Trust, AstraZeneca, Cancer Research UK
Breast Cancer
06/24
06/34
Romanova, Janina
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26

Download Options